AP2015008731A0 - Pan-elr+ cxc chemokine antibodies - Google Patents

Pan-elr+ cxc chemokine antibodies

Info

Publication number: AP2015008731A0
Authority: AP; ARIPO
Prior art keywords: elr; pan; cxc chemokine; chemokine antibodies; antibodies
Prior art date: 2013-03-15

Application number

AP2015008731A

Other languages

English (en)

Inventor

Jeffrey Streetman Boyles

Derrick Ryan Witcher

Beth Ann Strifler

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-05

Publication date

2015-09-30

2014-03-05 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-09-30 Publication of AP2015008731A0 publication Critical patent/AP2015008731A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Ultra Sonic Daignosis Equipment (AREA)

AP2015008731A 2013-03-15 2014-03-05 Pan-elr+ cxc chemokine antibodies AP2015008731A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361792800P	2013-03-15	2013-03-15
PCT/US2014/020605 WO2014149733A1 (en)	2013-03-15	2014-03-05	Pan-ELR+ CXC CHEMOKINE ANTIBODIES

Publications (1)

Publication Number	Publication Date
AP2015008731A0 true AP2015008731A0 (en)	2015-09-30

Family

ID=50343858

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008731A AP2015008731A0 (en)	2013-03-15	2014-03-05	Pan-elr+ cxc chemokine antibodies

Country Status (35)

Country	Link
EP (4)	EP3348569B1 (xx)
JP (1)	JP6105146B2 (xx)
KR (1)	KR101745230B1 (xx)
CN (2)	CN109134652B (xx)
AP (1)	AP2015008731A0 (xx)
AR (2)	AR094960A1 (xx)
AU (1)	AU2014237898B2 (xx)
CA (1)	CA2901468C (xx)
CL (1)	CL2015002531A1 (xx)
CY (1)	CY1120459T1 (xx)
DK (1)	DK2970447T3 (xx)
EA (1)	EA029965B1 (xx)
ES (3)	ES2993153T3 (xx)
HR (1)	HRP20181047T1 (xx)
HU (1)	HUE038834T2 (xx)
IL (2)	IL241167B (xx)
JO (1)	JO3580B1 (xx)
LT (1)	LT2970447T (xx)
MA (1)	MA38413A1 (xx)
ME (1)	ME03094B (xx)
MX (1)	MX364831B (xx)
MY (1)	MY171213A (xx)
NZ (1)	NZ711704A (xx)
PE (2)	PE20151531A1 (xx)
PH (1)	PH12015502090B1 (xx)
PL (1)	PL2970447T3 (xx)
PT (1)	PT2970447T (xx)
RS (1)	RS57291B1 (xx)
SG (1)	SG11201507686TA (xx)
SI (1)	SI2970447T1 (xx)
TN (1)	TN2015000377A1 (xx)
TR (1)	TR201807613T4 (xx)
TW (1)	TWI612059B (xx)
UA (1)	UA116008C2 (xx)
WO (1)	WO2014149733A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6416224B2 (ja) *	2013-05-17	2018-10-31	セントルナショナルデラルシュルシュサイエンティフィーク（シーエヌアールエス）	抗ｃｘｃｌ１抗体、抗ｃｘｃｌ７抗体および抗ｃｘｃｌ８抗体ならびにそれらの用途
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
CN111770936A (zh)	2018-01-12	2020-10-13	百时美施贵宝公司	抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
KR102049180B1 (ko) *	2018-04-02	2019-11-26	고려대학교 산학협력단	체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법
TWI737000B (zh) *	2018-10-22	2021-08-21	美商美國禮來大藥廠	用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
CA3154522A1 (en)	2019-10-15	2021-04-22	Christopher Carl Frye	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN113087795B (zh) *	2019-12-23	2025-06-10	上海普铭生物科技有限公司	针对趋化因子cx3cl1的抗体及其应用
WO2021163031A1 (en) *	2020-02-12	2021-08-19	Eli Lilly And Company	Crystallization of antibodies or antigen-binding fragments
TW202206457A (zh)	2020-04-24	2022-02-16	美商美國禮來大藥廠	用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN112358547A (zh) *	2020-09-30	2021-02-12	浙江大学	抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
WO2023192478A1 (en)	2022-04-01	2023-10-05	Bristol-Myers Squibb Company	Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040091503A1 (en) *	2002-08-20	2004-05-13	Genitrix, Llc	Lectin compositions and methods for modulating an immune response to an antigen
WO2007107002A1 (en) *	2006-03-22	2007-09-27	Osteopharm Inc.	Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
HUE037489T2 (hu) *	2007-08-29	2018-08-28	Sanofi Sa	Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
GB0806812D0 (en) *	2008-04-15	2008-05-14	Univ Leuven Kath	Citrullinated cytokines
KR20100133012A (ko) *	2008-05-14	2010-12-20	일라이 릴리 앤드 캄파니	항-ｃｘｃｒ4 항체
BR112012004387A2 (pt) *	2009-08-28	2015-09-08	Vlst Corp	anticorpos anticinas que se l igam a múltiplas quimiocinas cc.
JP2011097867A (ja) *	2009-11-05	2011-05-19	Kurume Univ	脊柱靱帯骨化症のマーカーペプチド
US20120315267A1 (en) *	2010-02-09	2012-12-13	Glaxosmithkline Llc	Novel uses
WO2013166099A1 (en) *	2012-05-01	2013-11-07	Glaxosmithkline Llc	Novel antibodies

2014
- 2014-02-27 JO JOP/2014/0058A patent/JO3580B1/ar active
- 2014-02-27 TW TW103106908A patent/TWI612059B/zh active
- 2014-02-28 AR ARP140100675A patent/AR094960A1/es active IP Right Grant
- 2014-03-05 PT PT147118996T patent/PT2970447T/pt unknown
- 2014-03-05 KR KR1020157024786A patent/KR101745230B1/ko active Active
- 2014-03-05 HU HUE14711899A patent/HUE038834T2/hu unknown
- 2014-03-05 PL PL14711899T patent/PL2970447T3/pl unknown
- 2014-03-05 ME MEP-2018-173A patent/ME03094B/me unknown
- 2014-03-05 MA MA38413A patent/MA38413A1/fr unknown
- 2014-03-05 CA CA2901468A patent/CA2901468C/en active Active
- 2014-03-05 SI SI201430741T patent/SI2970447T1/en unknown
- 2014-03-05 RS RS20180675A patent/RS57291B1/sr unknown
- 2014-03-05 EP EP18153438.9A patent/EP3348569B1/en active Active
- 2014-03-05 AU AU2014237898A patent/AU2014237898B2/en active Active
- 2014-03-05 ES ES19190355T patent/ES2993153T3/es active Active
- 2014-03-05 WO PCT/US2014/020605 patent/WO2014149733A1/en not_active Ceased
- 2014-03-05 DK DK14711899.6T patent/DK2970447T3/en active
- 2014-03-05 CN CN201811074266.5A patent/CN109134652B/zh active Active
- 2014-03-05 PE PE2015001961A patent/PE20151531A1/es active IP Right Grant
- 2014-03-05 NZ NZ711704A patent/NZ711704A/en unknown
- 2014-03-05 AP AP2015008731A patent/AP2015008731A0/xx unknown
- 2014-03-05 JP JP2016500640A patent/JP6105146B2/ja active Active
- 2014-03-05 MX MX2015013053A patent/MX364831B/es active IP Right Grant
- 2014-03-05 SG SG11201507686TA patent/SG11201507686TA/en unknown
- 2014-03-05 CN CN201480013248.XA patent/CN105143259B/zh active Active
- 2014-03-05 LT LTEP14711899.6T patent/LT2970447T/lt unknown
- 2014-03-05 EP EP24199045.6A patent/EP4467566A3/en active Pending
- 2014-03-05 ES ES14711899.6T patent/ES2675404T3/es active Active
- 2014-03-05 ES ES18153438T patent/ES2769123T3/es active Active
- 2014-03-05 EP EP14711899.6A patent/EP2970447B1/en active Active
- 2014-03-05 EA EA201591514A patent/EA029965B1/ru not_active IP Right Cessation
- 2014-03-05 TR TR2018/07613T patent/TR201807613T4/tr unknown
- 2014-03-05 EP EP19190355.8A patent/EP3608336B1/en active Active
- 2014-03-05 PE PE2019001763A patent/PE20191480A1/es unknown
- 2014-03-05 HR HRP20181047TT patent/HRP20181047T1/hr unknown
- 2014-03-05 MY MYPI2015703113A patent/MY171213A/en unknown
- 2014-05-03 UA UAA201508673A patent/UA116008C2/uk unknown
2015
- 2015-08-31 TN TN2015000377A patent/TN2015000377A1/en unknown
- 2015-09-03 IL IL24116715A patent/IL241167B/en active IP Right Grant
- 2015-09-09 CL CL2015002531A patent/CL2015002531A1/es unknown
- 2015-09-14 PH PH12015502090A patent/PH12015502090B1/en unknown
2018
- 2018-07-24 CY CY20181100767T patent/CY1120459T1/el unknown
2019
- 2019-09-16 IL IL269387A patent/IL269387B/en active IP Right Grant
2022
- 2022-05-10 AR ARP220101240A patent/AR125831A2/es unknown

Also Published As

Publication number	Publication date
CA2901468A1 (en)	2014-09-25
IL241167A0 (en)	2015-11-30
TN2015000377A1 (en)	2017-01-03
DK2970447T3 (en)	2018-06-18
ES2769123T3 (es)	2020-06-24
JP6105146B2 (ja)	2017-03-29
HUE038834T2 (hu)	2018-11-28
PL2970447T3 (pl)	2018-10-31
PH12015502090B1 (en)	2020-07-08
CN105143259A (zh)	2015-12-09
EP3348569A1 (en)	2018-07-18
EP2970447B1 (en)	2018-05-16
EP4467566A2 (en)	2024-11-27
JO3580B1 (ar)	2020-07-05
EA029965B1 (ru)	2018-06-29
EP3608336B1 (en)	2024-10-02
RS57291B1 (sr)	2018-08-31
KR101745230B1 (ko)	2017-06-08
AR125831A2 (es)	2023-08-16
MX2015013053A (es)	2016-05-18
PE20191480A1 (es)	2019-10-18
TWI612059B (zh)	2018-01-21
CN109134652B (zh)	2022-05-24
PE20151531A1 (es)	2015-10-28
SI2970447T1 (en)	2018-06-29
ES2675404T3 (es)	2018-07-11
UA116008C2 (uk)	2018-01-25
EP2970447A1 (en)	2016-01-20
EA201591514A1 (ru)	2016-03-31
AU2014237898B2 (en)	2016-05-05
AU2014237898A8 (en)	2015-08-27
TR201807613T4 (tr)	2018-06-21
KR20150119155A (ko)	2015-10-23
JP2016512026A (ja)	2016-04-25
IL269387A (en)	2019-11-28
SG11201507686TA (en)	2015-10-29
ME03094B (me)	2019-01-20
AU2014237898A1 (en)	2015-08-20
PH12015502090A1 (en)	2016-01-18
CA2901468C (en)	2018-02-20
IL241167B (en)	2019-10-31
TW201520226A (zh)	2015-06-01
HRP20181047T1 (hr)	2018-08-24
MX364831B (es)	2019-05-08
HK1212714A1 (en)	2016-06-17
PT2970447T (pt)	2018-08-07
IL269387B (en)	2021-05-31
AR094960A1 (es)	2015-09-09
BR112015020174A2 (pt)	2017-08-29
WO2014149733A1 (en)	2014-09-25
MY171213A (en)	2019-10-02
EP3348569B1 (en)	2019-11-27
NZ711704A (en)	2019-12-20
MA38413A1 (fr)	2017-10-31
LT2970447T (lt)	2018-07-25
CN105143259B (zh)	2018-09-21
CY1120459T1 (el)	2019-07-10
CL2015002531A1 (es)	2016-06-17
ES2993153T3 (en)	2024-12-23
CN109134652A (zh)	2019-01-04
EP3608336A1 (en)	2020-02-12
EP4467566A3 (en)	2025-04-23

Publication	Publication Date	Title
IL269528A (en)	2019-11-28	Anti- FCRH5 antibodies
IL269387B (en)	2021-05-31	Antibodies against pan-elr cxc chemokines
SG11201509361TA (en)	2015-12-30	Novel antibodies
GB201322583D0 (en)	2014-02-05	Antibodies
IL243409A0 (en)	2016-03-31	Apocylated anti–fgfr2iiib antibodies
ZA201601437B (en)	2018-08-29	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
GB201312226D0 (en)	2013-08-21	Improved antibodies
GB201318283D0 (en)	2013-11-27	Antibodies
TH1501005445A (th)	2018-03-08	Pan-ELR+CXC CHEMOKINE แอนติบอดี้